knowledge -WSS

knowledge

author：explore 2025-08-24 23:09:51 - browse：5

A view of different flags of the European Union Members. -- first opinion coverage from STAT — Ronald Wittek, Pool Photo via AP

Today, the criteria used to assess the clinical value of new pharmaceuticals and medical devices varies widely across Europe, making it more challenging for biopharma companies to efficiently launch products in multiple countries and contributing to the disparities in access across the continent.

But change is on the horizon: In less than 15 months, the European Union will establish and begin to implement a standardized, pan-EU framework, which all 27 of member states will be required to use to assess the clinical evidence of newly submitted products or devices. A key pillar of the EU’s Regulation on Health Technology Assessment (HTA), the Joint Clinical Assessment (JCA) aims to establish a single, transparent process to reduce redundant practices and bring life science innovation faster to patients in Europe — no matter where they live.

In a longstanding problem in Europe, access to — and the availability of — medication varies across the member states. For example, in Germany, 87% of products approved by the European Medicines Agency (EMA) have full availability (the product gained access on the public reimbursement list without any restrictions to the patient population). In Poland, that figure drops to 8%, according to a report published by the European Federation of Pharmaceutical Industries. Meanwhile, there is a tremendous difference in the gap between an oncology therapy receiving marketing authorization and a formal positive reimbursement decision, ranging from an average of 86 days in Denmark to 981 days in Latvia.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： Second xenotransplant done with gene

WSS

Pandemic and All Hazards Preparedness Act needs lean update

Lasker Awards 2023: Winners in biomedical research

Pandemic and All Hazards Preparedness Act needs lean update

Biden targets hefty hospital 'facility fees' that often surprise patients

Thermo Fisher plant for manufacturing gene therapies to expand

Emergency workers more likely to restrain Black patients: study

focus

knowledge

entertainment

The high cost of giving birth even with insurance

Emergency workers more likely to restrain Black patients: study

Peter Hotez and the public health issue of online harassment

It's been 20 years since Dolly the sheep. Where's my clone?

Virginia high school admissions case could be legal follow

Parents surprise family after baby discharged from NICU after 170 days

DIEP, the 'gold standard' of breast reconstruction, is under threat

Biden targets hefty hospital 'facility fees' that often surprise patients

Virginia high school admissions case could be legal follow

How Vertex's cystic fibrosis drug is changing patients' lives

focus

Pandemic and All Hazards Preparedness Act needs lean update

See Ryan Reynolds, Hugh Jackman suited up in 1st look at 'Deadpool 3': Photo

Senators: Long

EpiPen alternative approval delay highlights citizen petition issue

Emergency workers more likely to restrain Black patients: study

What Congress can do to address the rural doctor shortage

hotspot

entertainment

leisure time

knowledge